Loading clinical trials...
Loading clinical trials...
A Real-World Retrospective Observational Study Characterizing Patients With Stage 2 Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
Conditions
Interventions
Teplizumab
Locations
4
Italy
Investigational Site Number: 3800003
Palermo, Italy
Investigational Site Number: 7240001
Madrid, Spain
Investigational Site Number: 7240002
Madrid, Spain
Investigational Site Number: 8260002
London, United Kingdom
Start Date
March 16, 2026
Primary Completion Date
November 30, 2026
Completion Date
November 30, 2026
Last Updated
April 17, 2026
NCT07224321
NCT06474598
NCT06815081
NCT07051005
NCT05188027
NCT07212179
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions